Answers are grounded in this paper and cite their sources.
The MTD and toxicity profile of 17-AAG were schedule dependent. Intermittent dosing schedules were less toxic and are recommended for future phase II studies.
No takes yet. Share an insight, caveat, or question.
Solit et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: